ENHERTU Supplemental New Drug Application submitted in Japan as adjuvant therapy for patients with HER2...

ABL Bio–NEOK Bio receive U.S. IND clearance for phase 1 clinical trial of ABL209 (NEOK002)

PADCEV + Keytruda cuts risk of recurrence or death by nearly 50% in cisplatin-eligible muscle-invasive...

Henlius doses first patient in phase 2/3 trial of anti-HER2 mAb HLX22 in combination with...

WuXi XDC enters strategic collaboration with Earendil Labs on WuXiTecan-2 payload-linker technology platform

Ligachem Bio and Ono Pharmaceutical accelerate joint ADC research, receiving follow-up milestones